BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 9463099)

  • 1. Intensive combined modality therapy including low-dose TBI in high-risk Ewing's Sarcoma Patients.
    Kinsella TJ; Glaubiger D; Diesseroth A; Makuch R; Waller B; Pizzo P; Glatstein E
    Int J Radiat Oncol Biol Phys; 1983 Dec; 9(12):1955-60. PubMed ID: 9463099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.
    Czyzewski EA; Goldman S; Mundt AJ; Nachman J; Rubin C; Hallahan DE
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):569-77. PubMed ID: 10348286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH; Meyers PA
    J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance.
    Miser JS; Kinsella TJ; Triche TJ; Tsokos M; Forquer R; Wesley R; Horvath K; Belasco J; Longo DL; Steis R
    J Clin Oncol; 1988 Mar; 6(3):484-90. PubMed ID: 3280743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of the pelvic bones.
    Evans R; Nesbit M; Askin F; Burgert O; Cangir A; Foulkes M; Gehan E; Gilula L; Kissane J; Makley J
    Int J Radiat Oncol Biol Phys; 1985 Jan; 11(1):129-36. PubMed ID: 3881374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of sarcomas of the chest wall using intensive combined modality therapy.
    Young MM; Kinsella TJ; Miser JS; Triche TJ; Glaubiger DL; Steinberg SM; Glatstein E
    Int J Radiat Oncol Biol Phys; 1989 Jan; 16(1):49-57. PubMed ID: 2643597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.
    Meyers PA; Krailo MD; Ladanyi M; Chan KW; Sailer SL; Dickman PS; Baker DL; Davis JH; Gerbing RB; Grovas A; Herzog CE; Lindsley KL; Liu-Mares W; Nachman JB; Sieger L; Wadman J; Gorlick RG
    J Clin Oncol; 2001 Jun; 19(11):2812-20. PubMed ID: 11387352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of pelvic sarcomas in adolescents and young adults with intensive combined modality therapy.
    Stea B; Kinsella TJ; Triche TJ; Horvath K; Glatstein E; Miser JS
    Int J Radiat Oncol Biol Phys; 1987 Dec; 13(12):1797-805. PubMed ID: 3679916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ewing's sarcoma treatment in Scandinavia 1984-1990--ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV.
    Nilbert M; Saeter G; Elomaa I; Monge OR; Wiebe T; Alvegård TA
    Acta Oncol; 1998; 37(4):375-8. PubMed ID: 9743460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma.
    Horowitz ME; Kinsella TJ; Wexler LH; Belasco J; Triche T; Tsokos M; Steinberg SM; McClure L; Longo DL; Steis RG
    J Clin Oncol; 1993 Oct; 11(10):1911-8. PubMed ID: 8410118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
    Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
    J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
    Dunst J; Ahrens S; Paulussen M; Rübe C; Winkelmann W; Zoubek A; Harms D; Jürgens H
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):379-84. PubMed ID: 9788419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late follow-up of a short-term intensive regimen for Ewing's sarcoma.
    Marcus RB; Springfield DS; Graham-Pole JR; Heare TC; Enneking WF; Million RR
    Am J Clin Oncol; 1991 Oct; 14(5):446-50. PubMed ID: 1951181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse after high-dose therapy in relapsed Ewing's tumor patients: effects of maintenance chemotherapy in two selected patients?
    Laws HJ; van Kaick B; Pape H; Paulussen M; Göbel U
    Onkologie; 2003 Dec; 26(6):573-7. PubMed ID: 14709933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG).
    Shankar AG; Pinkerton CR; Atra A; Ashley S; Lewis I; Spooner D; Cannon S; Grimer R; Cotterill SJ; Craft AW
    Eur J Cancer; 1999 Nov; 35(12):1698-704. PubMed ID: 10674016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study.
    Evans RG; Nesbit ME; Gehan EA; Garnsey LA; Burgert O; Vietti TJ; Cangir A; Tefft M; Thomas P; Askin FB
    J Clin Oncol; 1991 Jul; 9(7):1173-80. PubMed ID: 2045857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma.
    Burdach S; Jürgens H; Peters C; Nürnberger W; Mauz-Körholz C; Körholz D; Paulussen M; Pape H; Dilloo D; Koscielniak E
    J Clin Oncol; 1993 Aug; 11(8):1482-8. PubMed ID: 8101562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group.
    Donaldson SS; Torrey M; Link MP; Glicksman A; Gilula L; Laurie F; Manning J; Neff J; Reinus W; Thompson E; Shuster JJ
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):125-35. PubMed ID: 9747829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of multimodal therapy in Ewing's sarcoma: a retrospective analysis of 20 patients.
    Ben-Arush M; Kuten A; Perez-Nahum M; Cohen Y; Bialik V
    J Surg Oncol; 1991 Sep; 48(1):51-5. PubMed ID: 1890840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81.
    Sauer R; Jürgens H; Burgers JM; Dunst J; Hawlicek R; Michaelis J
    Radiother Oncol; 1987 Oct; 10(2):101-10. PubMed ID: 3423301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.